Clinical efficacy of combined or single use of clofibrate and cytarabine in treatment of adult patients with myelodysplastic syndromes or acute leukemia: a Meta analysis
10.3760/cma.j.issn.1009-9921.2019.03.009
- VernacularTitle:氯法拉滨、阿糖胞苷联合或单用治疗成年骨髓增生异常综合征和急性白血病患者临床效果Meta分析
- Author:
Feifei LIU
1
;
Yan WANG
;
Rong CHEN
;
Jianzhen SHEN
Author Information
1. 福建省血液病研究所 福建省血液病学重点实验室 福建医科大学附属协和医院血液内科
- Keywords:
Myelodysplastic syndromes;
Acute leukemia;
Adult;
Clofarabine;
Cytarabine;
Meta-analysis
- From:
Journal of Leukemia & Lymphoma
2019;28(3):164-168
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of combined or single use of clofibrate and cytarabine in the treatment of adult patients with myelodysplastic syndromes (MDS) or acute leukemia (AL).Methods Clofarabine combined with cytarabine was used in the combined group and clofarabine or cyarabine alone was used in the control group.All the studies about cytarabine and clofarabine were searched in PubMed,Cochrance Library,Embase,CNKI,Wanfang and VIP database by computer,and then the data was extracted.Results The complete remission rate of the combined group was higher than that of the control group [33.1％ (93/281) vs.18.2％ (35/192),and the difference was statistically significant (RR =1.85,95％ CI 1.31-2.60,P ＜ 0.01).The overall response rate of the combined group was higher than that of the control group [44.0％ (124/282) vs.23.2％ (46/198)],and the difference was statistically significant (RR =1.92,95％ CI 1.44-2.56,P ＜ 0.01).However,the incidence of skin adverse reactions in the combined group was also higher than that in the control group [38.8％ (104/268) vs.3.1％ (6/192)],and the difference was statistically significant (RR =7.76,95％ CI 3.68-16.38,P ＜ 0.01).Conclusion The combination of clofarabine and cytarabine in the treatment of adult patients with MDS or AL has better clinical efficacy than single application,but it also has more serious skin adverse reactions.
